PureTech Health PLC PRTC & Roche Announce Significant Collaboration (2346V)
July 20 2018 - 2:00AM
UK Regulatory
TIDMPRTC
RNS Number : 2346V
PureTech Health PLC
20 July 2018
20 July 2018
PureTech Health plc
PureTech Health Announces Collaboration with Roche to Advance
Technology for Oral Administration of Antisense
Oligonucleotides
PureTech Health to receive up to $36 million in upfront
payments, research support, and early preclinical milestones and is
eligible to potentially receive over $1 billion in development
milestones
PureTech Health plc (LSE: PRTC) ("PureTech Health"), a
clinical-stage biopharmaceutical company developing novel medicines
focused on the Brain-Immune-Gut (BIG) Axis, today announced that it
has entered into a multiyear collaboration with F. Hoffmann-La
Roche Ltd and Hoffmann-La Roche Inc., to advance PureTech's
milk-derived exosome platform technology for the oral
administration of Roche's antisense oligonucleotide platform. Under
the terms of the agreement, PureTech Health will receive up to $36
million, including upfront payments, research support, and early
preclinical milestones. PureTech Health will be eligible to
potentially receive development milestone payments of over $1
billion and additional sales milestones and royalties for an
undisclosed number of products.
PureTech's milk exosome-based technology is uniquely designed to
facilitate the oral administration of complex payloads such as
nucleic acids, peptides, and small molecules. These exosomes are
believed to traffic via lymphatic circulation and could potentially
enable the targeting of immune cells in novel ways.
Daphne Zohar, Co-founder and Chief Executive Officer of PureTech
Health, said: "We are excited to accelerate the development of this
promising technology from our internal lymphatic and immune cell
trafficking programmes. The expertise and resources that Roche is
bringing to the collaboration will help us to potentially address
one of the biggest challenges in oligonucleotide-based therapeutic
development: oral administration of nucleic acids."
PureTech Health has been advancing internal research and
development projects that focus on the Brain-Immune-Gut (BIG) Axis,
with an emphasis on lymphatics and immune cell trafficking to
modulate immunity in a tissue-specific manner. These internal
pipeline programmes are being consolidated into a separate division
of PureTech Health called Ariya. PureTech's Internal division,
which includes the milk-derived exosome technology, has generated
compelling pre-clinical data and secured key intellectual property
for its lymphatic and immune cell trafficking programmes.
About PureTech's Milk Exosomes Technology
Milk exosomes represent a significant opportunity to potentially
resolve the long-standing challenge of oral bioavailability of
macromolecules and complex small molecules. Exosomes, which contain
mixtures of lipids, proteins and nucleic acids, play a critical
physiologic role in intercellular communication and the transport
of macromolecules between cells and tissues. Mammalian-derived
exosomes have attractive potential as vehicles for the
administration of a variety of drug payloads, especially nucleic
acids, since their natural composition will likely provide superior
tolerability over the variety of synthetic polymers currently in
use. Most sources of mammalian exosomes are not suitable or viable
as vehicles for oral administration of drugs due to their lack of
stability under the harsh physiologic conditions associated with
transit through the stomach and small intestine; however, the
milk-derived exosomes that form the basis for PureTech's
internally-developed technology have evolved naturally and
specifically to accomplish the task of oral transport of complex
biological molecules. The technology is based on research conducted
by PureTech Health and its academic collaborators, including Ramesh
Gupta, PhD, Agnes Brown Duggan Chair in Oncological Research at the
James Graham Brown Cancer Center, and Professor in the Department
of Pharmacology and Toxicology at University of Louisville, and
exclusively licensed to PureTech Health.
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced, clinical-stage
biopharmaceutical company developing novel medicines around the
Brain-Immune-Gut (BIG) Axis. The Company has developed deep insight
into the connection between these systems and the resulting role in
many chronic diseases, which represent the majority of healthcare
spend and have proven resistant to established therapeutic
approaches. By harnessing this emerging field of human biology,
PureTech Health has developed new categories of medicines with the
potential to have great impact on people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies across two divisions. Its Affiliates division includes
two product candidates that are preparing for potential regulatory
approval in the United States and Europe and a number of clinical
and pre-clinical programmes. These affiliates have developed
ground-breaking platforms and therapeutic candidates in
collaboration with some of the world's leading scientific
experts.
PureTech's Internal division is advancing a pipeline fuelled by
recent discoveries in lymphatics and immune cell trafficking to
modulate disease in a tissue-specific manner. These programmes
build on a new understanding of the trafficking and biodistribution
of various immune system components in order to develop targeted
therapies for diseases with major unmet needs including cancer and
autoimmune and neuroimmune disorders.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRDDGDRSSBBGIC
(END) Dow Jones Newswires
July 20, 2018 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024